Tag:

Vivus

Latest Headlines

Latest Headlines

Can a dwindling rep tally keep Vivus' obesity med in the game?

With a trio of new obesity meds on the scene, some industry watchers expected the market to see some serious expansion. But development has been slow--much slower than Qsymia maker Vivus expected--and halving its rep tally is just one step the drugmaker is taking to help ease the pain.

Flailing Vivus halves hard-hit Qsymia sales force as revenue lags

Struggling Vivus is short on cash, and it's got a pricey cardiovascular outcomes trial looming in its future. Its fix? Pare down costs once again--or, in the words of RBC Capital Markets analyst Simos Simeonidis, "amputate a limb so that the patient may live."

New obesity meds 'pretty safe,' but some side effects bear watching: AdverseEvents

An analysis by AdverseEvents shows the new generation of obesity meds are holding their own, safety-wise. Still, postmarketing data flag some serious cardiovascular and neuropsychiatric side effects that are worth monitoring, the healthcare informatics firm says.

Brutal honesty in drug marketing? For obesity meds, it's key to avoiding the 'magic pill' trap

Dieting and exercise to lose weight is more effective when done with support--and weight-loss drugmakers have taken that to heart in marketing their treatments. But according to a recent Journal of Public Policy & Marketing article, lifestyle support isn't enough. Drugmakers may want to look to their advertising pitches, too.

Endo plots a double-sized salesforce, new DTC push for Stendra relaunch

Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus. Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste.

Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC

Upon buying up Auxilium--which markets Vivus' erectile dysfunction drug Stendra--Endo decided wholesale inventory levels weren't where they ought to be. Its solution? A relaunch of the drug, complete with a new salesforce and DTC efforts.

Analyst: Vivus generic threats a positive for obesity market

No drugmaker wants a generic challenger for a product it relies on--and certainly not two generics challengers. But in the case of Vivus, which has sued Actavis and now Teva over patent infringement for weight-loss drug Qsymia, the generic interest could be an "incremental positive," one analyst believes.

Vivus to slash obesity salesforce by one-third, turn to digital instead

Critics say Vivus has lacked the marketing muscle to build up its weight-loss med Qsymia ever since it chose to launch without a large commercial partner. And now, the company has chosen to shrink its salesforce by a third, with about 50 reps headed for the door.

FDA backs ED upstart Stendra as a fast-acting alternative to Viagra

Companies have been studying Stendra for some sort of competitive edge. Now, they may have found one: The FDA backed the ED pill as a fast-acting treatment, taken 15 minutes before sex. Previously, the directions prescribed a 30-minute lead time.

Vivus hits Actavis with Qsymia patent-infringement lawsuit

Weak Qsymia sales have been the all-important issue for Vivus since the highly anticipated obesity therapy stumbled out of the gate, inspiring an all-out proxy war that wreaked havoc on the company's boardroom. And the California company isn't about to cede what market share it does have to Actavis--at least, not without a fight.